Literature DB >> 22772752

Regulation of lymphocyte function by adenosine.

Joel Linden1, Caglar Cekic.   

Abstract

Adenosine regulates the interaction between lymphocytes and the vasculature, and is important for controlling lymphocyte trafficking in response to tissue injury or infection. Adenosine can blunt the effects of T cell receptor activation primarily by activating adenosine A(2A) receptors and signaling via cyclic AMP and protein kinase A. Protein kinase A reduces proximal T cell receptor signaling by phosphorylation of C-terminal Src kinase, nuclear factor of activated T cells and cyclic AMP response element-binding protein. Protein kinase A activation can either enhance or inhibit the survival of T cells depending on the strength and duration of signaling. Inducible enzymes such as CD73 and CD39 regulate adenosine formation and degradation in vivo. The extravasation of lymphocytes through blood vessels is influenced by A(2A) receptors-mediated suppression of intercellular adhesion molecule 1 expression on lymphocytes and diminished production of interferon γ and interferon γ-inducible chemokines that are chemotactic to activated lymphocytes. Adenosine also decreases the barrier function of vascular endothelium by activating A(2B)Rs. In sum, adenosine signaling is influenced by tissue inflammation and injury through induction of receptors and enzymes and has generally inhibitory effects on lymphocyte migration into inflamed tissues due to protein kinase A-mediated effects on adhesion molecules, interferon γ production, and endothelial barrier function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22772752      PMCID: PMC4476649          DOI: 10.1161/ATVBAHA.111.226837

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  70 in total

1.  A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.

Authors:  Paul E Zarek; Ching-Tai Huang; Eric R Lutz; Jeanne Kowalski; Maureen R Horton; Joel Linden; Charles G Drake; Jonathan D Powell
Journal:  Blood       Date:  2007-10-01       Impact factor: 22.113

2.  Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function.

Authors:  Balázs Csóka; Leonóra Himer; Zsolt Selmeczy; E Sylvester Vizi; Pál Pacher; Catherine Ledent; Edwin A Deitch; Zoltán Spolarics; Zoltán H Németh; György Haskó
Journal:  FASEB J       Date:  2008-07-14       Impact factor: 5.191

Review 3.  Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function.

Authors:  Kei Ohnuma; Nam H Dang; Chikao Morimoto
Journal:  Trends Immunol       Date:  2008-05-02       Impact factor: 16.687

4.  CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes.

Authors:  Masahide Takedachi; Dongfeng Qu; Yukihiko Ebisuno; Hiroyuki Oohara; Michelle L Joachims; Stephanie T McGee; Emiko Maeda; Rodger P McEver; Toshiyuki Tanaka; Masayuki Miyasaka; Shinya Murakami; Thomas Krahn; Michael R Blackburn; Linda F Thompson
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

Review 5.  Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).

Authors:  David W Hoskin; Jamie S Mader; Suzanne J Furlong; David M Conrad; Jonathan Blay
Journal:  Int J Oncol       Date:  2008-03       Impact factor: 5.650

6.  Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis.

Authors:  Elena Gonzalez-Rey; Mario Delgado
Journal:  Trends Mol Med       Date:  2007-04-27       Impact factor: 11.951

7.  Restoration of adenosine deaminase-deficient human thymocyte development in vitro by inhibition of deoxynucleoside kinases.

Authors:  Michelle L Joachims; Patrick A Marble; Aletha B Laurent; Peter Pastuszko; Marco Paliotta; Michael R Blackburn; Linda F Thompson
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

8.  Adenosine deamination sustains dendritic cell activation in inflammation.

Authors:  Melanie D Desrosiers; Katherine M Cembrola; Michael J Fakir; Leslie A Stephens; Fatimina M Jama; Afshin Shameli; Wajahat Z Mehal; Pere Santamaria; Yan Shi
Journal:  J Immunol       Date:  2007-08-01       Impact factor: 5.422

9.  A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to Escherichia coli.

Authors:  Balázs Csóka; Zoltán H Németh; László Virág; Pál Gergely; S Joseph Leibovich; Pál Pacher; Chun-Xiao Sun; Michael R Blackburn; E Sylvester Vizi; Edwin A Deitch; György Haskó
Journal:  Blood       Date:  2007-05-24       Impact factor: 22.113

10.  Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.

Authors:  Silvia Deaglio; Karen M Dwyer; Wenda Gao; David Friedman; Anny Usheva; Anna Erat; Jiang-Fan Chen; Keiichii Enjyoji; Joel Linden; Mohamed Oukka; Vijay K Kuchroo; Terry B Strom; Simon C Robson
Journal:  J Exp Med       Date:  2007-05-14       Impact factor: 14.307

View more
  64 in total

1.  Multi-Inhibitory Effects of A2A Adenosine Receptor Signaling on Neutrophil Adhesion Under Flow.

Authors:  Tadayuki Yago; Hiroki Tsukamoto; Zhenghui Liu; Ying Wang; Linda F Thompson; Rodger P McEver
Journal:  J Immunol       Date:  2015-09-09       Impact factor: 5.422

2.  Intestinal immunopathology is associated with decreased CD73-generated adenosine during lethal infection.

Authors:  V Francois; H Shehade; V Acolty; N Preyat; P Delrée; M Moser; G Oldenhove
Journal:  Mucosal Immunol       Date:  2014-11-12       Impact factor: 7.313

3.  Alveolar Epithelial A2B Adenosine Receptors in Pulmonary Protection during Acute Lung Injury.

Authors:  Sandra Hoegl; Kelley S Brodsky; Michael R Blackburn; Harry Karmouty-Quintana; Bernhard Zwissler; Holger K Eltzschig
Journal:  J Immunol       Date:  2015-07-17       Impact factor: 5.422

4.  Antiproliferative effects of selective adenosine receptor agonists and antagonists on human lymphocytes: evidence for receptor-independent mechanisms.

Authors:  Anke C Schiedel; Svenja K Lacher; Carsten Linnemann; Percy A Knolle; Christa E Müller
Journal:  Purinergic Signal       Date:  2013-01-29       Impact factor: 3.765

Review 5.  Attenuating myocardial ischemia by targeting A2B adenosine receptors.

Authors:  Holger K Eltzschig; Stephanie K Bonney; Tobias Eckle
Journal:  Trends Mol Med       Date:  2013-03-26       Impact factor: 11.951

Review 6.  Adenosine signaling and adenosine deaminase regulation of immune responses: impact on the immunopathogenesis of HIV infection.

Authors:  Daniela F Passos; Viviane M Bernardes; Jean L G da Silva; Maria R C Schetinger; Daniela Bitencourt Rosa Leal
Journal:  Purinergic Signal       Date:  2018-08-10       Impact factor: 3.765

7.  Phenotypic and functional characteristics of CD39high human regulatory B cells (Breg).

Authors:  F Figueiró; L Muller; S Funk; E K Jackson; A M O Battastini; T L Whiteside
Journal:  Oncoimmunology       Date:  2016-02-26       Impact factor: 8.110

8.  Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells.

Authors:  Yuliia Kaljas; Chengqian Liu; Maksym Skaldin; Chengxiang Wu; Qing Zhou; Yuanan Lu; Ivona Aksentijevich; Andrey V Zavialov
Journal:  Cell Mol Life Sci       Date:  2016-09-23       Impact factor: 9.261

9.  Adenosine A3 agonists reverse neuropathic pain via T cell-mediated production of IL-10.

Authors:  Mariaconcetta Durante; Silvia Squillace; Filomena Lauro; Luigino Antonio Giancotti; Elisabetta Coppi; Federica Cherchi; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Grant Kolar; Carrie Wahlman; Adeleye Opejin; Cuiying Xiao; Marc L Reitman; Dilip K Tosh; Daniel Hawiger; Kenneth A Jacobson; Daniela Salvemini
Journal:  J Clin Invest       Date:  2021-04-01       Impact factor: 14.808

10.  Down-Regulation of CD62L Shedding in T Cells by CD39+ Regulatory T Cells Leads to Defective Sensitization in Contact Hypersensitivity Reactions.

Authors:  Karsten Mahnke; Jurgina Useliene; Sabine Ring; Paula Kage; Verena Jendrossek; Simon C Robson; Matilda Bylaite-Bucinskiene; Kerstin Steinbrink; Alexander H Enk
Journal:  J Invest Dermatol       Date:  2016-09-10       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.